Cost-effectiveness of PD-L1 testing to guide immunotherapy for patients with advanced non-small-cell lung cancer in China

Le résumé fourni par la source

Aim: This study aims to assess the cost-effectiveness of three major programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) testing assays in guiding immunotherapy for patients with advanced non-small-cell lung cancer (NSCLC) in China, and to provide empirical evidence on the selection of cost-effective diagnostics to support the immune checkpoint inhibitor monotherapy regimens for NSCLC patients. Materials & methods: From a healthcare system perspective, a decision tree model was constructed to simulate the cost and effectiveness of employing VENTANA PD-L1 (SP263) Assay, Dako PD-L1 IHC 22C3 assay, and Dako 22C3 antibody concentrate in advanced NSCLC patients in China. The cost-effectiveness of Ventana PD-L1 IHC SP263 assay compared with other testing methods was assessed through the incremental analysis. The robustness of the base case analysis results was validated by one-way sensitivity analysis and probabilistic sensitivity analysis. Results: The VENTANA PD-L1 (SP263) Assay, which can guide multiple immune checkpoint inhibitor monotherapies (e.g., atezolizumab and pembrolizumab) for advanced NSCLC patients, achieved a higher percentage of successfully diagnosed and treated, and a higher quality-adjusted life-year at a lower cost compared with Dako PD-L1 IHC 22C3 assay and Dako 22C3 antibody concentrate. The robustness of the base case results was confirmed by both one-way sensitivity analysis and probabilistic sensitivity analysis. Conclusion: The VENTANA PD-L1 (SP263) Assay is cost-effective compared with Dako PD-L1 IHC 22C3 assay and Dako 22C3 antibody concentrate for the immunotherapy treatment for advanced NSCLC patients in China.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.